SAUDI-MINISTRY-TOURISM
6.6.2024 14:47:31 CEST | Business Wire | Press release
The Saudi Ministry of Tourism is participating in the 46th Annual NYU International Hospitality Investment Conference, highlighting the Kingdom's exceptional progress and vast investment opportunities within its booming tourism sector. This conference presents a unique platform for Saudi Arabia to share its transformative journey towards becoming a premier global tourism destination while diversifying its economy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606244256/en/
Saudi Ministry of Tourism Deputy Minister for Tourism Destination Enablement Mahmoud Abdulhadi Speaking at the "Invest Saudi & Prosper in Tourism" Networking Lunch (Photo: AETOSWire)
At the forefront of the conference, Mahmoud Abdulhadi, Deputy Minister of Tourism Destination Enablement, delivered a keynote speech to the attendees. He discussed the abundant opportunities in Saudi Arabia, providing insights on investing in tourism to develop new destinations. Mahmoud emphasized how international investors can benefit from the opportunities created, underlining the Kingdom’s commitment to becoming a leading global tourism destination.
Complementing the keynote, the "Invest Saudi & Prosper in Tourism" Networking Lunch, hosted by the Ministry of Tourism, offered a deep dive into Saudi Arabia's investment potential under Vision 2030. The event featured speakers from the Saudi Ministry of Tourism and Ministry of Investment, focusing on the transformation and development in the market, sector performance, and investment opportunities. The government’s support for investors through the Tourism Investment Enablers Program (TIEP), which focuses on enhancing the ease and cost of doing business in the tourism sector, provides incentives, and opens up this untapped market, was also discussed in detail.
The TIEP is designed to lower investment barriers, reduce government fees by 22%, and offer significant incentives. The program includes the flagship Hospitality Investment Enablers (HIE) initiative, which aims to generate USD 11.2 billion in private-sector investments and create 120,000 jobs in identified tourism destinations with high potential. These initiatives make Saudi Arabia an attractive and lucrative destination for investors.
Mahmoud Abdulhadi, Deputy Minister of Tourism Destination Enablement, said, "Saudi Arabia stands at the threshold of an unprecedented transformation in its tourism sector, offering unparalleled opportunities for investors. Our commitment to Vision 2030 is not just a blueprint for development; it's an open invitation for global partners to be part of a historic journey. By investing in Saudi Arabia, you are investing in a future where innovation, culture, and hospitality converge to create extraordinary experiences. The Tourism Investment Enablers Program and the Hospitality Investment Enablers initiative are designed to provide you with the support, incentives, and reduced barriers needed to succeed in this thriving market. Together, we can build a world-class tourism destination that benefits not only our economy but also the global community."
As part of the Ministry of Tourism’s participation at the event, Gloria Guevara Manzo, Chief Special Advisor at the Ministry of Tourism, Saudi Arabia, took part in a fireside chat titled "The Travel and Tourism Trends Driving the Market." The session examined the trends that hospitality investors and other stakeholders need to consider to drive their strategies, providing valuable insights into the evolving landscape of global tourism.
This discussion underscored Saudi Arabia’s significant strides in its tourism sector, notably attracting 100 million international visitors in 2023, seven years ahead of schedule. This success sets the stage for the Kingdom’s new target of 150 million tourists, reflecting its growing global appeal.
Further highlighting its success, Saudi Arabia rose nine places to 41st in the World Economic Forum's Travel & Tourism Development Index 2024, demonstrating the impact of its strategic investments and robust regulatory framework. Recognized as one of the safest countries to visit in the Middle East, the Kingdom’s appeal to international investors continues to grow.
With an investment of USD 800 billion into its tourism sector, Saudi Arabia is creating 1.6 million job opportunities and adding 500,000 hotel rooms. These investments are driving the Kingdom’s economic and social transformation, focusing on developing cultural sites, sports venues, theme parks, and nature reserves. Additionally, the Ministry of Tourism’s efforts to simplify the e-visa process for 66 countries further boost tourism inflows and investment opportunities, making the Kingdom more accessible to international visitors.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606244256/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom